Dr. Rakeshwar Bandichhor

Dr. Reddy’s Laboratories, India

                                                                    Biography :

Dr. Rakeshwar has more than 80 papers including patents and book chapters published/accepted in various International Journals. Notably, in the area of Organic Chemistry, Dr. Rakeshwar has coauthored a chapter in the book entitled “Green Chemistry in Pharmaceutical industry”.
He has won the various awards in his career e.g. Chairman Excellence Award in the category of individual functional excellence, Best Cost Leadership Award  for the development of Lopinavir, Ritonavir & their components and Anveshan Award at Dr. Reddy’s. As a part of organizational building efforts, he also supervises masters & Ph.D. students in their dissertations. He has been invited in several conferences e.g. IIT-Mumbai, IGCW-2009, BIT-Ranchi, BITS Pilani, 9th Heterocyclic Conference, University of Florida, JNTU-Hyderabad, ISCB-2011, Apollo Hospitals Educational & Research Foundation, Hyderabad, etc. to deliver lectures. He is also currently acting as an Associate  Editor of the GERF Bulletin of Bioscience.   
Recently, he has become a member National Advisory Board of Indian Society of Chemists and Biologists.


Dr.Parathasarathi Das

IIT – ISM, Dhanbad, India



·         Doctor of Philosophy (Ph.D.), Organic Chemistry, CSIR-National Chemical Laboratory, University of Poona, India (1993-1999)

·         Master of Science (M.Sc.), Organic Chemistry, University of Burdwan, Burdwan, India (1991-1993)



·         Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA (2002- 2003)

·         Department of Chemistry, Tohoku University, Sendai, Japan (2000- 2002)

·         Institut für Organische Chemie, RWTH-Aachen, Aachen, Germany (1999-2000)




·         Associate Professor, Indian Institute of Technology (ISM) Dhanbad, India (Dec 2017-date)

·         Principal Scientist, Indian Institute of Integrative Medicine (CSIR), Jammu, India (2012-Nov 2017)

·         Scientist Fellow, Indian Institute of Integrative Medicine (CSIR), Jammu, India (2011-2012)



·         Research Investigator, Dr. Reddy’s Laboratories Ltd./Aurigene Discovery Technologies, Hyderabad, India (2007-2011)  

·         Principal Scientist, Dr. Reddy’s Laboratories Ltd., Hyderabad, India (2005-2006)

·         Senior Scientist, Dr. Reddy’s Laboratories Ltd., Hyderabad, India (2003-2005)

Dr.Toyonobu Usukii.jpg

Dr.Toyonobu Usukii

Sophia University,Japan.

                                                                                    Biography :

Toyonobu Usuki obtained his B.S., M.S., and Ph.D. degrees in chemistry under the supervision of Professor Masahiro Hirama and Professor Masayuki Inoue from Tohoku University, Sendai, Japan, in 2000, 2002, and 2005, respectively. After postdoctoral studies in the laboratory of Professor Koji Nakanishi at the Department of Chemistry, Columbia University, New York, USA, from 2005 to 2007 as a JSPS Postdoctoral Fellow for Research Abroad, he joined the Department of Materials and Life Sciences, Sophia University, Tokyo, Japan, as an Assistant Professor (Principal Investigator) in 2008. Since 2013, he is an Associate Professor at the same university. His research interests include natural products chemistry, organic chemistry, medicinal chemistry, and bioorganic chemistry.


Dr. Gopal Natesan

Director,MAHSA University,Malaysia

                                                                             Biography :

Gopal Natesan has completed his Doctoral degree (Ph.D.) in Pharmaceutical Chemistry from Hamdard University (Jamia Hamdard) New Delhi, India in 2000 and currently serving as Professor of Medicinal Chemistry & Deputy Dean of Research & Innovation and Students Affairs in Faculty of Pharmacy, MAHSA University, Kuala Lumpur, Malaysia. His research focuses on the synthesis of newer small chemical entities, quinazolinones heterocyclic pharmacophore and their preliminary screening in both in-vivo and in-vitro models mainly focusing on pain & inflammation and also for newer microbial agents. He has published >40 articles in indexed journals and presented >80 papers in conferences and invited speakers at international scientific meetings and conferences and serves as a reviewer for several scientific international journals and also as Editorial/Advisory board of various journals.

Dr. Gautham Sethi NUS.jpg

Dr. Gautham Sethi

Associate Professor, NUS, Singapore

Research Interests

  1. Mechanism(s) of regulation of oncogenic transcription factors by carcinogens and inflammatory agents.
  2. Identification of novel pharmacological compounds that can suppress activation of these transcription factors.
  3. Development and characterization of orthotopic/transgenic and xenograft mouse models of cancer.

Selected Publications

  1. Chai EZ, Shanmugam MK, Arfuso F, Dharmarajan A, Wang C, Kumar AP, Samy RP, Lim LH, Wang L, Goh BC, Ahn KS, Hui KM, Sethi G. Targeting transcription factor STAT3 for cancer prevention and therapy. (2015). Pharmacol Ther. 2016 Jun;162:86-97(IF=9.7).

  2. Zhang J, Ahn KS, Kim C, Shanmugam MK, Siveen KS, Arfuso F, Samy RP, Deivasigamani A, Lim LH, Wang L, Goh BC, Kumar AP, Hui KM, Sethi G. Nimbolide-induced oxidative stress abrogates STAT3 signaling cascade and inhibits tumor growth in transgenic adenocarcinoma of mouse prostate model. (2015). Antioxid Redox Signal. 2016 Apr 10;24(11):575-89(IF= 7.4).

  3. Li F, Shanmugam MK, Siveen KS, Wang F, Ong TH, Loo SY, Swamy MM, Mandal S, Kumar AP, Goh BC, Kundu T, Ahn KS, Wang LZ, Hui KM, Sethi G. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. (2015). Oncotarget. 6: 5147-5163. (IF=6.6).

  4. Dai X, Ahn KS, Kim C, Siveen KS, Ong TH, Shanmugam MK, Li F, Shi J, Kumar AP, Wang LZ, Goh BC, Magae J, Hui KM, Sethi G. Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3. (2015). Mol Oncol. 9:818-833. (IF=5.7).

  5. Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L, Tan PH, Hui KM, Yip GW, Miyamoto S, Kumar AP, Tergaonkar V. DEAD-box Helicase DP103 Defines the Metastatic Potential of Human Breast Cancers. (2014). J Clin Invest. 124: 3807- 3824 (IF=13.2).

  6. Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G*, Bishayee A. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. (2014). Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1845: 136-154 (IF= 7.5). *Co-corresponding author.

  7. Siveen KS, Ahn KS, Ong TH, Shanmugam MK, Li F, Yap WN, Kumar AP, Fong CW, Tergaonkar V, Hui KM, Sethi G. γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. (2014) Oncotarget. 5: 1897-1911. (IF=6.6).

  8. Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM, Sethi G. Potential Role of Signal Transducer and Activator of Transcription (STAT)3 Signaling Pathway in Inflammation, Survival, Proliferation and Invasion of Hepatocellular Carcinoma. (2013). Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1835: 46-60 (IF=7.5).

  9. Manu KA, Shanmugam M, Ramachandran L, Li F, Fong CW, Kumar AP, Tan P, Sethi G. First evidence that g-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kB pathway. (2012). Clin Cancer Res. 18: 2220-2229 (IF= 8.7).

  10. Ramachandran L, Manu KA, Shanmugam MK, Li F, Siveen KS, Vali S, Kapoor S, Abbasi T, Surana R, Smoot DT, Ashktorab H, Tan P, Ahn KS, Yap CW, Kumar AP, Sethi G. Isorhamnetin inhibits proliferation, invasion, and induces apoptosis through the modulation of peroxisome proliferator-activated receptor-gamma activation pathway in gastric cancer. (2012). J Biol Chem. 287: 38028-38040 (IF=4.4).

blog Blog